Arthritis
Researchers from Bristol-Myers Squibb Company describe findings in arthritis
Published in Lab Business Week, August 19th, 2007
"DPC 333 [(2R)-2-{(3R)-3-amino-3-[4-(2-methylquinolin-4-ylmethoxy) phenyl]-2-oxopyrrolidin-1-yl}-N-hydroxy-4-methylpentanamide] is a potent human tumor necrosis factor alpha-converting enzyme inhibitor with potential therapeutic implications for rheumatoid arthritis. Methotrexate (MTX), a drug for the treatment of rheumatoid arthritis, is eliminated primarily unchanged via renal and biliary excretion in humans as well as in rats and dogs," researchers in the United States report.
"The objective of the present study was to investigate the potential effect of DPC 333 on the disposition of MTX. In dogs, DPC 333 administered orally at 1.7 mg/kg 15 min before the intravenous...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
Source: Lab Business Week (2007-08-19)
More Articles from Lab Business Week
- Allergies
Auriga Laboratories Expands the Zinx Family with the Launch of Two New Prescription Convenience Kits - Zinx Allergy Kit and Zinx Kids' Sneeze Kit - Antibiotics
Findings from Dr. Reddy's Laboratories Ltd. advance knowledge in antibiotics - Breast Cancer Therapy
Research conducted at Chester Beatty Laboratories has updated our knowledge about breast cancer therapy - Cell Biology
Cold Spring Harbor Laboratory reports research in cell biology - Chemotherapy
Reports outline chemotherapy research from Mitsubishi Kagaku Bio-Clinical Laboratories, Inc. - Clinical Trial Research
Rheoscience and Dr. Reddy's Commence the First Phase III Trial of Balaglitazone (DRF 2593) - More from this issue of Lab Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
